Ernexa Therapeutics Inc. · NASDAQ:ERNA
Ernexa Therapeutics — Brooklyn ImmunoTherapeutics — Merger or Acquisition (July 2021)
13 slides from Ernexa Therapeutics's merger presentation, Jul 19, 2021
Slide 1: Next Generation Personalized Medicines
July 19, 2021 Next Generation Personalized Medicines A platform company in cell, gene-editing & cytokine therapies
Slide 2: Disclaimer
Disclaimer This presentation is intended to provide summary information about the business of Brooklyn ImmunoTherapeutics, Inc. (“BTX”), including BTX’s recent acquisition of Novellus, Inc. (“Novellus”). The information in this presentation is in no respects complete, comprehensive or exhaustive, an
Slide 3: BTX Acquisition of Novellus: Rationale and Pipeline
BTX Acquisition of Novellus: Rationale and Pipeline Co-founded by Matt Angel and Chris Rohde in 2014Vision: Advancing a portfolio of engineered mesenchymal stem cell (MSC) cell therapy programs to address multiple inflammatory, autoimmune, and neurologic indicationsPipeline: 3
Slide 4: Strategic Value of Acquisition
Strategic Value of Acquisition BTX’s acquisition of Novellus will enable the full range of MSC products unrestricted by field of usePlatform technology leading to a family of product candidatesNovellus’s MSC products are induced pluripotent stem cell (iPSC)-derivedAllogenic ‘off-the-shelf’ products,
Slide 5: Transaction Terms
Transaction Terms Valued at $125 millionCash payment $23 millionBTX common stock $102 million$14.53/share, a $4.48 premium per share (44.6% premium to the closing price of BTX stock on 7/16/21)BTX shareholders before the transaction to own 86.4% of the combined entity (on an as-converted basis)No de
Slide 6: BTX's Balance Sheet Enables Future Clinical Growth
BTX’s Balance Sheet Enables Future Clinical Growth BTX raised $51 million from equity lines of credit in second quarter 2021Post-closing cash on hand ~$25 million BTX projects it has cash runway to fund expansion through end of 2023 6
Slide 7: Economic Benefits to BTX
Economic Benefits to BTX Through the Novellus transaction, BTX acquired 25% ownership of NoveCite (developing product for acute respiratory distress syndrome, or ARDS, due to COVID-19)Eliminates payments potentially due to Novellus under the April 26, 2021 technology licensing agreement among BTX, N
Slide 8: Novellus Technology: iPSC-derived MSCs
Novellus Technology: iPSC-derived MSCsCells can be gene-edited to provide additional properties 8
Slide 9: Targeted Clinical Indications
Targeted Clinical Indications Non gene-modified MSC for bone marrow stroma rejuvenationGene-modified MSC for multiple solid tumor indicationsPotential for MSC applications in settings of autoimmunity 9
Slide 10: Other Potential Applications of Factor/Novellus Technology
Other Potential Applications of Factor/Novellus Technology Direct gene editing in the liver, brain and eyeAutologous iPSC / Gene-modified autologous iPSC for: Bone marrow engraftmentOther indications 10 ToRNAdo is a trademark of Factor Bioscience Inc.
Slide 11: BTX Most Advanced Asset: IRX-2 Human-Derived Cytokines
BTX Most Advanced Asset: IRX-2 Human-Derived Cytokines Phase 2 Company Sponsored Study in 1 IST Indication targeted to begin in 2022Phase 3 Study in Neoadjuvant Head and Neck Cancer targeted to begin in 2023 11 Renal Cell CancerLiver CancerHead and Neck CancerGastrointestinal Cancer Currently in Pha
Slide 12: Brooklyn ImmunoTherapeutics: A platform company in cell, gene-editing and cytokine therapies
Brooklyn ImmunoTherapeuticsA platform company in cell, gene-editing and cytokine therapies 12 We are a clinical-stage biopharmaceutical company developing treatments for patients suffering from cancer and rare diseases IRX-2, our most advanced program, is a human cell-derived cytokine therapy in Pha
Slide 13: Next Generation Personalized Medicines
July 19, 2021 Next Generation Personalized Medicines A platform company in cell, gene-editing & cytokine therapies
Brooklyn ImmunoTherapeutics — Merger or Acquisition (July 2021) on 6ix